美国肝细胞癌患者治疗延迟的种族、民族及社会经济差异
基于监测、流行病学和最终结果-医疗保险数据库纳入2001至2015年确诊的8450例肝细胞癌患者,1205例(14.3%)在确诊12个月内接受治疗者出现治疗延迟;黑人患者和高贫困社区居住者治疗延迟的比值比更高,治疗延迟与更差的总生存独立相关。
要点
- 8450例中14.3%出现治疗延迟,手术切除者延迟比例6.8%,肝移植者21.6%。
- 黑人患者较高贫困社区居住者治疗延迟的比值比分别为1.96和1.55。
- 治疗延迟与更差生存独立相关(风险比1.15,95%CI 1.05-1.25)。
核心结论
- 近七分之一肝细胞癌患者经历治疗延迟,黑人患者和高贫困社区居住者治疗延迟的比值比更高,治疗延迟与更差生存相关。
研究设计与样本
- 使用监测、流行病学和最终结果-医疗保险数据库识别2001至2015年确诊的肝细胞癌患者,纳入8450例在确诊12个月内接受治疗者。
主要发现
- 1205例(14.3%)出现治疗延迟,延迟比例从手术切除者的6.8%到肝移植者的21.6%。
- 黑人患者较白人患者治疗延迟的比值比为1.96(95%CI 1.21-3.15)。
- 高贫困社区居住者较低贫困社区居住者治疗延迟的比值比为1.55(95%CI 1.25-1.92)。
- 治疗延迟与更差总生存独立相关(风险比1.15,95%CI 1.05-1.25)。
关键数值与推荐
- 治疗延迟定义为确诊后超过3个月接受肝细胞癌导向治疗。
- 采用多因素logistic回归分析治疗延迟相关因素,采用5个月landmark的Cox比例风险回归分析治疗延迟与总生存的关联。
临床怎么用
- 原文结论强调需要干预以改善治疗时间,未据此给出具体临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Failures have been reported across the cancer care continuum in patients with hepatocellular carcinoma (HCC); however, the impact of treatment delays on outcomes has not been well-characterized. We described the prevalence of treatment delays in a racially and ethnically diverse cohort of patients and its association with overall survival. METHODS: Using the Surveillance, Epidemiology, and End Results-Medicare database, we identified patients diagnosed with HCC between 2001 and 2015. We performed multivariable logistic regression analysis to identify factors associated with treatment delay (ie, receipt of HCC-directed therapy >3 months after diagnosis). Cox proportional hazards regression analysis with a 5-month landmark was used to characterize the association between treatment delay and overall survival, accounting for immortal time bias. RESULTS: Of 8450 patients with treatment within 12 months of HCC diagnosis, 1205 (14.3%) experienced treatment delays. The proportion with treatment delays ranged from 6.8% of patients undergoing surgical resection to 21.6% of those undergoing liver transplantation. In multivariable analysis, Black patients (odds ratio, 1.96; 95% confidence interval [CI], 1.21-3.15) and those living in high poverty neighborhoods (odds ratio, 1.55; 95% CI, 1.25-1.92) were more likely to experience treatment delays than white patients and those living in low poverty neighborhoods, respectively. Treatment delay was independently associated with worse survival (hazard ratio 1.15, 95% CI, 1.05-1.25). CONCLUSIONS: Nearly 1 in 7 patients with HCC experience treatment delays, with higher odds in Black patients and those living in high poverty neighborhoods. Treatment delays are associated with worse survival, highlighting a need for interventions to improve time-to-treatment.
引用
- Wagle NS, Park S, Washburn D, et al. Racial, Ethnic, and Socioeconomic Disparities in Treatment Delay Among Patients With Hepatocellular Carcinoma in the United States. Clin Gastroenterol Hepatol. 2022. PMID: 35933076. doi:10.1016/j.cgh.2022.07.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。